Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells

Endocrinology

Volumn 152, Issue 9, 2011, Pages 3362-3372

  Koehler, Jacqueline A ^a   Kain, Taylor ^a   Drucker, Daniel J ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

AGAR MEDIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL LEVEL; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; COLON CANCER; COLONY FORMATION; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLON; CYCLIC AMP; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLUCAGON-LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; PEPTIDES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; VENOMS;

EID: 80052483571     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1201     Document Type: Article

References (46)

1. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D 2010 Diabetes and cancer: A consensus report. Diabetes Care 33:1674-1685
2. Pollak M 2010 Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res (Phila) 3:1060-1065
3. Smith U, Gale EA 2009 Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699-1708
4. Gallagher EJ, LeRoith D 2010 The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21:610-618
5. Drucker DJ 2006 The biology of incretin hormones. Cell Metab 3:153-165
6. Brubaker PL, Drucker DJ 2004 Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology 145:2653-2659 (Pubitemid 38686211)
7. Ligumsky H, Wolf I, Israeli S, Haimsohn M, Ferber S, Karasik A, Kaufman B, Rubinek T 3 June 2011 The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat 10.1007/s10549-011-1585-0
8. Campbell PT, Deka A, Jacobs EJ, Newton CC, Hildebrand JS, McCullough ML, Limburg PJ, Gapstur SM 2010 Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology 139:1138-1146
9. Zhou XH, Qiao Q, Zethelius B, Pyörälä K, Söderberg S, Pajak A, Stehouwer CD, Heine RJ, Jousilahti P, Ruotolo G, Nilsson PM, Calori G, Tuomilehto J 2010 Diabetes, prediabetes and cancer mortality. Diabetologia 53:1867-1876
10. Simonsen L, Pilgaard S, Orskov C, Rosenkilde MM, Hartmann B, Holst JJ, Deacon CF 2007 Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am J Physiol Gastrointest Liver Physiol 293:G288-G295 (Pubitemid 47105178)
11. Koehler JA, Drucker DJ 2006 Activation of GLP-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes 55:1369-1379 (Pubitemid 44195376)
12. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ 2006 GLP-1 receptor activation improves β-cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4:391-406 (Pubitemid 44752565)
13. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, Girard J, Tanti JF, Delzenne NM, Postic C, Burcelin R 2005 Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554-3563 (Pubitemid 43121843)
14. Brattain MG, Strobel-Stevens J, Fine D, Webb M, Sarrif AM 1980 Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 40:2142-2146 (Pubitemid 10082214)
15. Chomczynski P, Sacchi N 1987 Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159
16. Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ 2008 Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338-1349 (Pubitemid 351397945)
17. Yusta B, Boushey RP, Drucker DJ 2000 The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 275:35345-35352
18. Yusta B, Estall J, Drucker DJ 2002 GLP-2 receptor activation engages Bad and glycogen synthase kinase 3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277:24896-24906
19. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ 2009 GLP-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58:2148-2161
20. Koehler JA, Harper W, Barnard M, Yusta B, Drucker DJ 2008 Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res 68:7897-7904
21. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, Drucker DJ 2003 International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55:167-194 (Pubitemid 36268402)
22. Zhang B, Halder SK, Zhang S, Datta PK 2009 Targeting transforming growth factor-β signaling in liver metastasis of colon cancer. Cancer Lett 277:114-120
23. Kashima Y, Miki T, Shibasaki T, Ozaki N, Miyazaki M, Yano H, Seino S 2001 Critical role of cAMP-GEFII/Rim2 complex in incretin-potentiated insulin secretion. J Biol Chem 276:46046-46053
24. 2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. J Biol Chem 279:46497-46508
25. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M 2004 Glucagon-like peptide-1 prevents β-cell glucolipotoxicity. Diabetologia 47:806-815 (Pubitemid 38756992)
26. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem 278:471-478 (Pubitemid 36043598)
27. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB 2010 Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33:428-433
28. Drucker DJ 2003 Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 17:161-171
29. Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N 2008 The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574-579
30. Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, De Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M 2010 Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151:1473-1486
31. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS 2005 Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis. Science 310:1504-1510 (Pubitemid 41746348)
32. Ghatei MA, Goodlad RA, Taheri S, Mandir N, Brynes AE, Jordinson M, Bloom SR 2001 Proglucagon-derived peptides in intestinal epithelial proliferation: glucagon-like peptide-2 is a major mediator of intestinal epithelial proliferation in rats. Dig Dis Sci 46:1255-1263 (Pubitemid 32523272)
33. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H, McCallum K, Sumner-Smith M, Drucker DJ, Crivici A 1999 Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 96:1569-1573 (Pubitemid 29098492)
34. Bullock BP, Heller RS, Habener JF 1996 Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 137:2968-2978
35. Buteau J, Roduit R, Susini S, Prentki M 1999 Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX1) DNA binding activity in β(INS-1)-cells. Diabetologia 42:856-864
36. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ 2009 GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58:975-983
37. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH 2003 Glucagon-like peptide-1 decreases endogenous amyloid-β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res 72:603-612 (Pubitemid 36578646)
38. Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, Drucker DJ, Husain M 2010 GLP-1(9-36) protects cardiomyocytes and endothelial cells from ischemia-reperfusion injury via cytoprotective pathways independent of the GLP-1 receptor. Endocrinology 151:1520-1531
39. Evers BM 2006 Neurotensin and growth of normal and neoplastic tissues. Peptides 27:2424-2433
40. Thulesen J, Hartmann B, Hare KJ, Kissow H, Ørskov C, Holst JJ, Poulsen SS 2004 Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 53:1145-1150 (Pubitemid 38961969)
41. Iakoubov R, Lauffer LM, Trivedi S, Kim YI, Brubaker PL 2009 Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 150:4033-4043
42. Jin G, Ramanathan V, Quante M, Baik GH, Yang X, Wang SS, Tu S, Gordon SA, Pritchard DM, Varro A, Shulkes A, Wang TC 2009 Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. J Clin Invest 119:2691-2701
43. Fang JY, Richardson BC 2005 The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322-327 (Pubitemid 40590269)
44. Voisin L, Julien C, Duhamel S, Gopalbhai K, Claveau I, Saba-El-Leil MK, Rodrigue-Gervais IG, Gaboury L, Lamarre D, Basik M, Meloche S 2008 Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. BMC Cancer 8:337
45. Balmanno K, Cook SJ 2009 Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 16:368-377
46. Prabakaran D, Wang B, Feuerstein JD, Sinclair JA, Bijpuria P, Jepeal LI, Wolfe MM 2010 Glucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells. Regul Pept 163:74-80